AZTR — Azitra, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1701478 ·
Last close
$0.61
Market Cap
$3.68M
52W High
$3.91
52W Low
$0.52
ADV30
5,449,659
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,419,168 | -3,347,660 | 8,916,046 | 6,727,810 | 1,581,707 |
| Mar 2026 | 0 | — | -3,933,924 | -3,927,240 | 12,126,804 | 10,051,003 | 1,646,521 |
| Dec 2025 | 0 | — | -2,226,591 | -2,233,504 | 5,025,386 | 2,068,083 | 1,224,156 |
| Sep 2025 | 0 | — | -2,768,484 | -2,764,528 | 4,300,279 | 1,401,878 | 2,021,103 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,105,767
Investing CF
$-279,616
Financing CF
$17,067,461
CapEx
$-279,616
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.27
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,796,096
Inventory
—
Receivables
$144,730
ST Investments
—
EBIT TTM
$-12,254,011
Pretax Income TTM
$-12,264,613
Interest Exp TTM
$10,602
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,966,665 | -10,955,370 | 5,025,386 | 1,224,156 | 3,801,230 | -11,224,125 |
| Dec 2024 | 7,500 | -10,985,140 | -8,967,492 | 7,358,802 | 1,660,504 | 5,698,298 | -10,183,740 |
| Dec 2023 | 686,000 | -7,450,546 | -11,283,781 | 5,115,486 | 2,202,340 | 2,913,146 | -7,362,375 |
| Dec 2022 | 284,000 | -9,453,604 | -10,680,366 | 7,167,443 | 43,427,753 | -36,260,310 | -8,349,469 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-12,272,932
OpCashFlow TTM
—
Assets (Latest)
$8,916,046
Forward EPS
$-0.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NCNA | NuCana plc | $3.70M | $0.89 | — |
| XBIO | Xenetic Biosciences, Inc. | $3.77M | $1.61 | — |
| SXTC | China SXT Pharmaceuticals, Inc. | $3.78M | $2.86 | — |
| TRAW | Traws Pharma, Inc. | $3.59M | $0.23 | — |
| PMHS | Polomar Health Services, Inc. | $3.55M | $0.13 | — |
News headlines (Yahoo Finance, 1h cache)
Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
2026-11-12 21:30 · Yahoo
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models
2026-11-10 13:30 · Yahoo
AZTR: Update on Rash, Fine Lines & Elasticity
2026-11-02 08:00 · Yahoo
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
2026-10-29 12:30 · Yahoo
Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
2026-10-26 12:45 · Yahoo
Azitra, Inc. Announces Reverse Stock Split
2026-10-16 12:00 · Yahoo
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
2026-09-28 09:32 · Yahoo
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
/C O R R E C T I O N -- Azitra, Inc./
2026-07-15 15:33 · Yahoo
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
2026-07-15 14:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.